Join the Hypertrophic Cardiomyopathy group to help and get support from people like you.
Hypertrophic Cardiomyopathy News
Related terms: Cardiomyopathy, hypertrophic, HCM
U.S. Food and Drug Administration Updates Camzyos (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
PRINCETON, N.J.-- April 17, 2025 – (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information...
MEK Inhibition Beneficial for Children With Subset of Severe Hypertrophic Cardiomyopathy
MONDAY, Jan. 13, 2025 – For children with severe hypertrophic cardiomyopathy caused by gain-of-function RAS/mitogen-activated protein kinase (MAPK) mutations (RASopathy), trametinib reduces...
AI-Enabled Stethoscope Boosts Diagnosis of Pregnancy-Related Cardiomyopathy
TUESDAY, Sept. 10, 2024 – In pregnant and postpartum women, artificial intelligence (AI)-guided screening using a digital stethoscope improves the diagnosis of pregnancy-related cardiomyopathy,...
Experimental Drug Helps Folks Battling Enlarged Heart Move More
FRIDAY, May 17, 2024 – An experimental drug can help patients better live with a genetic condition that causes the heart to enlarge and thicken, a new clinical trial shows. People with the...
Aficamten Beneficial for Obstructive Hypertrophic Cardiomyopathy
THURSDAY, May 16, 2024 – Treatment with the oral selective cardiac myosin inhibitor aficamten results in significantly greater improvement in peak oxygen uptake compared with placebo among patients...
Guidelines Developed for Management of Hypertrophic Cardiomyopathy
THURSDAY, May 9, 2024 – In a new clinical guideline issued by the American College of Cardiology and the American Heart Association and published online May 8 in the Journal of the American College...
FDA Approves Camzyos (mavacamten) for the Treatment of Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules)...